LncRNA *FOXD3-AS1* Promotes Tumorigenesis of Glioma via Targeting miR-128-3p/*SZRD1* Axis [Retraction]

Li Z, Li M, Xia P, Wang L, Lu Z. *Cancer Manag Res.* 2021;13:9037–9048.

The Editor and Publisher of *Cancer Management and Research* wish to retract the published article. Concerns were raised regarding alleged image duplication in Figure 3 and Figure 7. Specifically:

- Figure 3D, panel HS683 si-NC appears to have been duplicated with Figure 7D, panel HS683 miR-128-3p mimic +OE-*SZRD1*.
- Figure 3D, panel HS683 si-*FOXD3-AS1* appears to have been duplicated with Figure 7D, panel HS683 miR-128-3p mimic.
- Figure 3D, panel HS683 miR-128-3p inhibitor appears to have been duplicated with Figure 7D, panel HS683 OE-*SZRD1*.
- Figure 3F, panel U251 Control appears to have been duplicated with Figure 7F, panel U251 Control.
- Figure 3F, panel U251 miR-128-3p inhibitor appears to have been duplicated with Figure 7F, panel U251 OE-*SZRD1*.

The authors responded to our queries but could not provide a satisfactory explanation for the alleged duplication or provide adequate raw data for their study. The findings of the study were deemed invalid and the Editor requested for the article to be retracted.

Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.